2 unknown, 1 not yet recruiting. 2 Phase 3, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Not yet recruiting 1, Unknown 1 |
| Early Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow mFOLFOX regimen: new trials by email Literature Review of mFOLFOX regimen trials Research Report on mFOLFOX regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers mFOLFOX regimen, Mitazalimab - Biliary Tract Cancer (BTC) | Phase 2 / Phase 3 | Not yet recruiting | UNICANCER | 160 | 2026-07-01 | 2026-02-27 |
| Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC Lenvatinib, mFOLFOX regimen, ROX regimen - Hepatocellular Carcinoma Stage IIIa | Early Phase 1 | Unknown | Zhejiang Cancer Hospital | 60 | 2021-07-01 | 2021-08-16 |
| mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases mFOLFOXIRI regimen, mFOLFOX regimen, Bevacizumab - Colorectal Carcinoma, Liver Metastases | Phase 3 | Unknown | Fudan University | 308 | 2021-04-15 | 2021-09-27 |
Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1)
Fudan University (1) · UNICANCER (1) · Zhejiang Cancer Hospital (1)
China (2) · France (1)
Jianmin Xu, MD, Ph.D. (1) · Jiaping Zheng, Doctor (1)
PMID 19095497, PMID 25027973, PMID 26674592, PMID 27918777, PMID 29471013, PMID 30207593, PMID 30220234, PMID 30959462, PMID 31063184, PMID 31070690, PMID 32497895